Molecular-Based Magnetic Resonance Multimodal Probes for Tumor Biomarker Imaging.

Area of Science:

• Oncology
• Biomedical Imaging
• Chemical Biology

Background:

• Cancer poses a significant global health burden, with the tumor microenvironment (TME) playing a critical role in its progression.
• Magnetic resonance imaging (MRI) offers excellent soft-tissue contrast but suffers from low sensitivity for detecting TME biomarkers.
• There is a need for advanced imaging strategies to overcome MRI's limitations for early cancer detection and therapeutic monitoring.

Purpose of the Study:

• To review recent design strategies for small-molecule responsive probes.
• To highlight the potential of these probes in multimodal imaging for cancer diagnostics.
• To discuss the future of MR-based multimodal agents in precision oncology.

Main Methods:

• Systematic review of recent literature on small-molecule responsive probes for TME imaging.
• Analysis of multimodal imaging strategies integrating MRI with other modalities.
• Evaluation of probe design principles focusing on pharmacokinetics and targeting precision.

Main Results:

• Small-molecule multimodal probes offer advantages over nanoparticle-based agents in pharmacokinetics and targeting precision.
• TME-responsive probes can bridge the gap between molecular recognition and macroscopic in vivo imaging.
• Multimodal imaging strategies consolidate multidimensional data for enhanced cancer visualization.

Conclusions:

• Small-molecule responsive probes represent a promising avenue for improving MRI sensitivity and specificity in oncology.
• These probes are crucial for early cancer detection and longitudinal monitoring of therapeutic responses.
• MR-based multimodal agents are poised to become essential tools for advancing personalized precision oncology.